Main menu
Common skin conditions
NEWS
Join DermNet PRO
Read more
Quick links
Author(s): Dr Monisha Datta Purokayastha, Senior House Officer; Dr Jake Moss, Dermatology Registrar; and Dr Emily Davies, Dermatologist, Cheltenham General Hospital, England (2023)
Reviewing dermatologist: Dr Ian Coulson
Edited by the DermNet content department
Introduction
Procedure
Uses
Contraindications
Benefits
Disadvantages
Side effects and risks
Ultraviolet B (UVB) phototherapy delivers shortwave ultraviolet radiation to treat skin conditions such as psoriasis. Phototherapy works by suppressing DNA synthesis, which in turn reduces inflammation.
Narrowband UVB phototherapy (311–312 nm) is increasingly used compared to broadband UVB phototherapy (270–350 nm). This is because exposure and treatment times are shorter and result in longer periods of remission.
UVB phototherapy is delivered within a specially designed cabinet. Fluorescent light tubes are positioned to target affected areas with ultraviolet radiation (eg, hands or feet). For full body treatments, patients are undressed with genitalia covered, and eyes or full face should be protected with goggles or a face mask.
Most patients will have treatment three times a week, at least 24 hours apart. Session length is initially ≤5 minutes, and may be uptitrated as required to a maximum of 30 minutes per session. The number and length of sessions vary for each individual, taking into account their skin type, skin condition, and previous response to treatment.
Phototesting to determine the minimum dose that produces skin redness (MED testing) is recommended and a starting dose of 70% of the MED is often used. The dose is escalated by 20% each treatment, provided there are no side effects or episodes of burning.
Targeted phototherapy devices (eg, excimer laser, brush or comb devices) have also been developed as treatment options for more challenging areas while sparing uninvolved skin.
Common indications:
Other indications:
Psoriasis is a chronic inflammatory skin disorder, which varies considerably in extent and severity. UVB is suitable for most people with extensive psoriasis. It may not suit those with very fair skin or those whose psoriasis gets worse in sunlight.
Most patients will have clearance or improvement in their psoriasis after 12 to 24 treatments. After treatment is discontinued the skin may remain clear for months. If psoriasis flares up again, further UVB treatment may be necessary.
UVB is occasionally used for severe cases of dermatitis, especially atopic dermatitis (eczema). Frequency and dosage of treatment are usually longer than for psoriasis.
UVB is effective in treating vitiligo by immune suppression and stimulation of cytokines. Treatment is given twice a week for 3–4 months and continued until re-pigmentation is complete or for 1–2 years. It may take several months to see an improvement and caution must be taken with fair skin.
Absolute contraindications:
Relative contraindications:
Short-term side effects:
Long-term side effects:
Approved datasheets are the official source of information for medicines, including approved uses, doses, and safety information. Check the individual datasheet in your country for information about medicines.
We suggest you refer to your national drug approval agency such as the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA), UK Medicines and Healthcare products regulatory agency (MHRA) / emc, and NZ Medsafe, or a national or state-approved formulary eg, the New Zealand Formulary (NZF) and New Zealand Formulary for Children (NZFC) and the British National Formulary (BNF) and British National Formulary for Children (BNFC).